Skip to main navigation

Skip to content

Side Menu

About
Our Programs
Our Platform
Scientific Presentations
Publications
Inside Seres
Open Positions
Investors and News
Contact Us
Contact Medical Affairs

Press Releases

Seres' news, events and other information can be found throughout the pages below.

Investor Relations

Stock Information
News and Events
- Press Releases
- Events & Presentations
Financial Information
- SEC Filings
- Annual Reports
Corporate Governance
Shareholder Services

Press Releases

Keyword Search

Year

Sep 08, 2026

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 01, 2026

Seres Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference

Aug 05, 2026

Seres Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates, Including Further Action to Reduce Ongoing Facilities Costs

Jul 08, 2026

Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer Treatment

Jun 25, 2026

Seres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres’ SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis

Jun 05, 2026

Seres Therapeutics Announces Two Transactions to Strengthen Balance Sheet, Reduce On-Going Lease Costs and Extend Projected Operating Cash Runway Well Into the First Quarter of 2027

May 12, 2026

Seres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference

May 05, 2026

Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

May 04, 2026

Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease

Apr 20, 2026

Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026

Pagination

Current page 1
Page 2
Next page
Last page

Shareholder Tools

RSS Feeds
E-mail Alerts
Print

© 2026 Seres Therapeutics.

Footer Left Menu

Privacy Policy
Terms of Use

Follow us on Linkedin
Follow us on Twitter
Follow us on Facebook